Jump to content

25I-NB3OMe

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vortioxetine (talk | contribs) at 23:42, 1 February 2018 (Added legality in the USA). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

25I-NB3OMe
Clinical data
ATC code
  • none
Identifiers
  • 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(3-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H22INO3
Molar mass427.282 g·mol−1
3D model (JSmol)
  • COC1=CC=CC(=C1)CNCCC2=CC(=C(C=C2OC)I)OC
  • InChI=1S/C18H22INO3/c1-21-15-6-4-5-13(9-15)12-20-8-7-14-10-18(23-3)16(19)11-17(14)22-2/h4-6,9-11,20H,7-8,12H2,1-3H3
  • Key:CJTZKPLDKCBUAF-UHFFFAOYSA-N

25I-NB3OMe (2C-I-NB3OMe, NB3OMe-2C-I) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1][2]

Legality

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[3]

United States

25I-NB3OMe is not a controlled substance, but is a positional isomer of 25I-NBOMe and thus may be considered a Schedule I drug under the Federal Analogue Act, meaning that it would be subject to the same penalties for possession, distribution, and manufacture as 25I-NBOMe.

References

  1. ^ https://bitnest.netfirms.com/external.php?id=%2501%253B5%25168%250F%2518%250DG%257F%255B18%2521UYHZP%251CUTscc%250BWk
  2. ^ https://bitnest.netfirms.com/external.php?id=%2501%253B5%25168%250F%2518%250DG%257F%255B18%2521UYHRO%2500JAsca%2515%255C
  3. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.